Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 7, 2011, Pages 1540-1546

  Hu, Xinli ^a,b   Atzler, Dorothee ^c   Xu, Xin ^a,b   Zhang, Ping ^a,b   Guo, Haipeng ^a,b   Lu, Zhongbing ^a,b   Fassett, John ^a,b   Schwedhelm, Edzard ^c   Böger, Rainer H ^c   Bache, Robert J ^a,b   Chen, Yingjie ^a,b,d  

^a Lillehei Heart Institute   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

asymmetric dimethylarginine, dimethylarginine dimethylaminohydrolase 1; knockout mice; nitric oxide

Indexed keywords

DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CONTROLLED STUDY; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; FEMALE; GENE DELETION; GENE FUNCTION; GENE SILENCING; HEART; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY STRUCTURE; LUNG STRUCTURE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; POSTNATAL DEVELOPMENT; POSTNATAL GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE LEVEL; TISSUE STRUCTURE; UMBILICAL VEIN ENDOTHELIAL CELL; URINE LEVEL; WILD TYPE;

AMIDOHYDROLASES; ANIMALS; ARGININE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HYPERTENSION; INFUSION PUMPS, IMPLANTABLE; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; PHENOTYPE; RISK FACTORS; RNA INTERFERENCE; SUBSTRATE SPECIFICITY; TIME FACTORS; TRANSFECTION;

EID: 79959707563     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.222638     Document Type: Article

References (45)

1. Moncada S. Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci. 2006;361:735-759. (Pubitemid 44858917)
2. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3-:5-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA. 1977;74:3203-3207.
3. Brown GC, Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett. 1994;356:295-298. (Pubitemid 24376992)
4. Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AHV. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: implications for neurodegenerative diseases. FEBS Lett. 1994;345:50-54.
5. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med. 2009;15:391-404.
6. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophy Res Commun. 1988;153:1251-1256.
7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20:S60-S62. (Pubitemid 23014109)
8. Gardiner S, Kemp P, Bennett T, Palmer R, Moncada S. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol. 1993;110:1457-1464. (Pubitemid 23360978)
9. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33:652-658. (Pubitemid 29164831)
10. Ding H, Wu B, Wang H, Lu Z, Yan J, Wang X, Shaffer JR, Hui R, Wang DW. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. Circ Res. 2010;106:1145-1152.
11. Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, Bengtsson C, Bjorkelund C, Thelle D, for The Swedish-Irish-Norwegian Collaboration. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the Population Study of Women in Gothenburg. Arterioscler Thromb Vasc Biol. 2008;28:961-967. (Pubitemid 351544114)
12. Wanby P, Teerlink T, Brudin L, Brattström L, Nilsson I, Palmqvist P, Carlsson M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis. 2006;185:271-277.
13. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sciences. 1998;62:2425-2430. (Pubitemid 28273149)
14. Chen Y, Li Y, Zhang P, Traverse JH, Hou M, Xu X, Kimoto M, Bache RJ. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol. 2005;289:H2212-H2219. (Pubitemid 41507375)
15. Kumagai H, Sakurai M, Takita T, Maruyama Y, Uno S, Ikegaya N, Kato A, Hishida A. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis. 2006;48:797-805. (Pubitemid 44740047)
16. Anderssohn M, Schwedhelm E, Lüneburg N, Vasan RS, Böger RH. Review article: asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diabetes Vasc Dis Res. 2010;7:105-118.
17. Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007;114:295-306. (Pubitemid 46843253)
18. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592-1600.
19. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem. 1989;264:10205-10209. (Pubitemid 19159295)
20. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343:209-214. (Pubitemid 29473897)
21. Valkonen V-P, Tuomainen T-P, Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med. 2005;10:S45-S48. (Pubitemid 43137267)
22. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation. 2003;107:1195-1201. (Pubitemid 36297214)
23. Gray GA, Patrizio M, Sherry L, Miller AA, Malaki M, Wallace AF, Leiper JM, Vallance P. Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction. Acta Histochem. 2010;112:413-423.
24. Tran CTL, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics. 2000;68:101-105.
25. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293:H3227-H3245. (Pubitemid 350230862)
26. Hu X, Xu X, Zhu G, Atzler D, Kimoto M, Chen J, Schwedhelm E, Luneburg N, Boger RH, Zhang P, Chen Y. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation. 2009;120:2222-2229.
27. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198-203.
28. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang B-y, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003;108:3042-3047. (Pubitemid 37553576)
29. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:211-219. (Pubitemid 46720141)
30. Maas R, Tan-Andreesen J, Schwedhelm E, Schulze F, Böger RH. A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:220-228. (Pubitemid 46720143)
31. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004;42:1377-1383. (Pubitemid 40057825)
32. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM, Cooke JP. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. 2005;111:1431-1438. (Pubitemid 40396810)
33. Stühlinger MC, Conci E, Haubner BJ, Stocker E-M, Schwaighofer J, Cooke JP, Tsao PS, Pachinger O, Metzler B. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc Res. 2007;75:417-425. (Pubitemid 46961932)
34. Lundberg JO, Weitzberg E. NO-synthase independent NO generation in mammals. Biochem Biophys Res Commun. 2010;396:39-45.
35. Lu Z, Fassett J, Xu X, Hu X, Zhu G, French J, Zhang P, Schnermann J, Bache RJ, Chen Y. Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle. Circulation. 2008;118:1713-1721.
36. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation. 2010;121:1474-1483.
37. Lundblad C, Bentzer P. Effects of L-arginine on cerebral blood flow, microvascular permeability, number of perfused capillaries, and brain water content in the traumatized mouse brain. Microvasc Res. 2007;74:1-8. (Pubitemid 46855789)
38. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
39. Pope AJ, Karrupiah K, Kearns PN, Xia Y, Cardounel AJ. Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production. J Biol Chem. 2009;284:35338-35347.
40. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M, Dennehy K, Li M, Modlinger P, Leiper J, Vallance P, Adler O, Leone A, Tojo A, Welch WJ, Wilcox CS. Isoform-specific regulation by NG,NGdimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res. 2007; 101:627-635. (Pubitemid 351325880)
41. Ogawa T, Kimoto M, Sasaoka K. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2. J Biol Chem. 1990;265:20938-20945. (Pubitemid 120014101)
42. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem. 2010;285:5385-5391.
43. Ogawa T, Kimoto M, Watanabe H, Sasaoka K. Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats. Arch Biochem Biophy. 1987;252:526-537.
44. Breckenridge R, Kelly P, Nandi M, Vallance P, Ohun T, Leiper J. A role for dimethylarginine dimethylaminohydrolase 1 (DDAH1) in mammalian development. Int J Dev Biol. 2010;54:215-220.
45. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O, Nakata S, Tanimoto A, Wang K-Y, Ueta Y, Sasaguri Y, Nakashima Y, Yanagihara N. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci USA. 2005;102:10616-10621. (Pubitemid 41061603)